Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Visceral leishmaniasis

M E Wilson1, J A Streit

  • 1Division of Infectious Diseases, University of Iowa, Iowa City, USA.

Gastroenterology Clinics of North America
|September 1, 1996
PubMed
Summary
This summary is machine-generated.

Visceral leishmaniasis is a fatal disease that is difficult to treat and prevent, especially in resource-limited areas. New, less toxic treatments and a protective vaccine are urgently needed to combat this growing public health concern.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Frequent medication combinations in travel medicine are associated with QTc prolongation.

Travel medicine and infectious disease·2019
Same author

Comparative analyses of whole genome sequences of Leishmania infantum isolates from humans and dogs in northeastern Brazil.

International journal for parasitology·2017
Same author

Epigenetic regulation of the estrogen receptor alpha promoter in the cerebral cortex following ischemia in male and female rats.

Neuroscience·2008
Same author

Short communication: insulin alters hepatic progesterone catabolic enzymes cytochrome P450 2C and 3A in dairy cows.

Journal of dairy science·2008
Same author

Metabolic and reproductive consequences of the serotonin transporter promoter polymorphism (5-HTTLPR) in adult female rhesus monkeys (Macaca mulatta).

Endocrine·2007
Same author

Lactation feed disappearance and weaning to estrus interval for sows fed spray-dried plasma.

Journal of animal science·2007
Same journal

Living Donor Intestinal and Liver Transplantation.

Gastroenterology clinics of North America·2026
Same journal

Living Abdominal Organ Donation: A Plan B That Saves Lives.

Gastroenterology clinics of North America·2026
Same journal

Long-Term Outcomes of Living Liver Donors.

Gastroenterology clinics of North America·2026
Same journal

Perioperative Management of Living Liver Donor Patients.

Gastroenterology clinics of North America·2026
Same journal

Living Donor Liver Transplantation for Colorectal Cancer Liver Metastasis.

Gastroenterology clinics of North America·2026
Same journal

Living Donor Liver Graft in Adult Populations: Donor Selection and Workup.

Gastroenterology clinics of North America·2026
See all related articles

Area of Science:

  • Tropical Medicine
  • Infectious Diseases
  • Parasitology

Background:

  • Visceral leishmaniasis (VL) is a severe, fatal parasitic disease if left untreated.
  • Management is challenging due to treatment toxicity, complex administration, and limited access to healthcare in endemic regions.
  • Increasing VL incidence in HIV-infected individuals and the persistence of the parasite in chronic cutaneous forms complicate control efforts.

Purpose of the Study:

  • To highlight the significant challenges in treating and preventing visceral leishmaniasis.
  • To underscore the urgent need for improved therapeutic strategies and vaccine development.

Main Methods:

  • This study is a review of the current challenges and unmet needs in visceral leishmaniasis management.
  • It synthesizes epidemiological data and treatment complexities.

Related Experiment Videos

Main Results:

  • Current treatments for VL are toxic, require intensive monitoring, and are difficult to administer in resource-limited settings.
  • Eradication of the Leishmania parasite is challenging with existing drugs, particularly in co-infected individuals.
  • Chronic cutaneous leishmaniasis facilitates long-term parasite reservoirs in humans and animals, aiding sandfly transmission.

Conclusions:

  • There is a critical need for the development of more effective and less toxic treatments for visceral leishmaniasis.
  • A protective vaccine is essential for the long-term control and potential eradication of this devastating disease.